Oxford BioDynamics signs development agreement with two pharmaceutical companies

Oxford BioDynamics, a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry,  has entered into a development agreement with two pharmaceutical companies, that are collaborating on an anti PD-L1 therapy.

Oxford BioDynamics said in its press release that it will identify biomarkers in whole blood of non-small cell lung carcinoma (NSCLC) patients to assist in differentiating between responders and non-responders to an anti PD-L1 therapy, using its EpiSwitch biomarker platform.

The agreement has the potential to be extended in the form of a licensing agreement, which would see the development of an EpiSwitch-class blood-based test, based on the work undertaken as part of the current agreement, for use by the pharmaceutical companies, tha company said.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said: “The momentum of EpiSwitch, as the leading epigenetic platform, continues to grow and the fact that our EpiSwitch platform is ideally positioned to aid these pharmaceutical companies only validates the platform further.”

Oxford BioDynamics did not disclose financial terms of the agreement, except saying that the two companies are among top ten global pharmaceutical companies.